Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Leases (2019 - 2025)

Historic Current Leases for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Tg Therapeutics' Current Leases fell 1324.13% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1324.13%. This contributed to the annual value of $1.2 million for FY2024, which is 1998.62% down from last year.
  • As of Q3 2025, Tg Therapeutics' Current Leases stood at $1.1 million, which was down 1324.13% from $1.1 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Current Leases high stood at $1.6 million for Q3 2022, and its period low was $1.1 million during Q3 2025.
  • Its 5-year average for Current Leases is $1.4 million, with a median of $1.5 million in 2021.
  • Per our database at Business Quant, Tg Therapeutics' Current Leases skyrocketed by 1008.17% in 2022 and then tumbled by 1998.62% in 2024.
  • Over the past 5 years, Tg Therapeutics' Current Leases (Quarter) stood at $1.4 million in 2021, then grew by 10.02% to $1.6 million in 2022, then fell by 8.54% to $1.4 million in 2023, then dropped by 19.99% to $1.2 million in 2024, then dropped by 7.69% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.